mipomersen sodium

DRUG5 trials

Conditions

Congenital AbnormalitiesCoronary Artery DiseaseCoronary Heart DiseaseDyslipidemiasGenetic Diseases, InbornHealthyHeterozygous Familial HypercholesterolemiaHypercholesterolemia

Phase 1

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

CompletedNCT01090661

Kastle Therapeutics, LLCHealthy

Start: 2010-03-31End: 2010-05-31Updated: 2016-08-03

Phase 2

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

CompletedNCT00477594

Kastle Therapeutics, LLCCongenital Abnormalities, Dyslipidemias, Genetic Diseases, Inborn +11

Start: 2007-05-31End: 2011-07-31Updated: 2016-09-09

Phase 3

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

CompletedNCT00694109

Kastle Therapeutics, LLCCongenital Abnormalities, Dyslipidemias, Genetic Diseases, Inborn +11

Start: 2008-04-30End: 2014-09-30Updated: 2016-09-09

Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease

CompletedNCT00706849

Kastle Therapeutics, LLCCoronary Artery Disease, Heterozygous Familial Hypercholesterolemia

Start: 2008-07-31End: 2010-05-31Updated: 2016-09-09

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

CompletedNCT00770146

Kastle Therapeutics, LLCCoronary Heart Disease, Hypercholesterolemia

Start: 2008-11-30End: 2010-10-31Updated: 2016-09-09

Related Papers

Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia.

2016-05-0996 citations

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

European Heart Journal2013-12-23138 citations

Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.

2013-09-04177 citations

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.

2012-11-13148 citations

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.

2012-10-11211 citations